To determine whether the administration of small amounts of glucose through an oral spray device (GSD) facilitates weight loss in overweight/obese subjects involved in a lifestyle modification programme. We randomly assigned 56 overweight/obese subjects to either the treatment group (n = 32) or the control group (n = 24). All subjects in both groups followed a structured dietary programme of 6,280.2 kJ (1,500 kcal)/day and exercised minimum 150 min a week and were followed-up for a period of 60 days. Subjects assigned to the treatment group were asked to spray, during early symptoms of neuroglycopenia, 10 puffs by GSD. GSD is a device that delivers to the buccal mucosa 50 mg of glucose per puff. A mean weight loss of 3.5 +/- A 3.0 kg in GSD-treated group compared to 1.7 +/- A 2.1 kg in control group (p = 0.01) was observed. Significant differences regarding reduction of BMI (-1.3 +/- A 1.0 vs -0.7 +/- A 0.8 kg/m(2); p = 0.01) and waist circumference (-3.5 +/- A 3.2 vs -0.9 +/- A 3.5 cm; p = 0.02) were also detected. A short-term use of GSD, in association with dietary restriction and exercise, is helpful in improving weight loss and in reducing waist circumference in overweight/obese subjects.

New technologies aiding dietary programmes for weight control: the oral glucose spray

Pozzilli P
2014-01-01

Abstract

To determine whether the administration of small amounts of glucose through an oral spray device (GSD) facilitates weight loss in overweight/obese subjects involved in a lifestyle modification programme. We randomly assigned 56 overweight/obese subjects to either the treatment group (n = 32) or the control group (n = 24). All subjects in both groups followed a structured dietary programme of 6,280.2 kJ (1,500 kcal)/day and exercised minimum 150 min a week and were followed-up for a period of 60 days. Subjects assigned to the treatment group were asked to spray, during early symptoms of neuroglycopenia, 10 puffs by GSD. GSD is a device that delivers to the buccal mucosa 50 mg of glucose per puff. A mean weight loss of 3.5 +/- A 3.0 kg in GSD-treated group compared to 1.7 +/- A 2.1 kg in control group (p = 0.01) was observed. Significant differences regarding reduction of BMI (-1.3 +/- A 1.0 vs -0.7 +/- A 0.8 kg/m(2); p = 0.01) and waist circumference (-3.5 +/- A 3.2 vs -0.9 +/- A 3.5 cm; p = 0.02) were also detected. A short-term use of GSD, in association with dietary restriction and exercise, is helpful in improving weight loss and in reducing waist circumference in overweight/obese subjects.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12610/8925
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact